Evidence map›Paper›PMID 25082860›Full record

ArticleBlood2014

p53 at the crossroads of MPN treatment.

Isabelle Plo

Open access · bronzeAbstract readComment
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Isabelle PloINSERM, UNITÉ MIXTE DE RECHERCHE 1009.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).

Indexed as

Janus Kinase 2Mutation, MissenseAnimalsAntiviral AgentsFemaleHematopoietic Stem CellsHumansImidazolinesInterferon-alphaMalePolycythemia VeraPolyethylene GlycolsPrimary MyelofibrosisProto-Oncogene Proteins c-mdm2Recombinant ProteinsAntiviral AgentsImidazolinesInterferon-alphaJAK2 protein, humanJanus Kinase 2MDM2 protein, humanpeginterferon alfa-2aPolyethylene GlycolsProto-Oncogene Proteins c-mdm2Recombinant ProteinsRG7112

Identifiers

PMID25082860
PMCPMC4118478
OpenAlexW2012783050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.